Quiz|Articles|August 30, 2026

Test Your Knowledge: YCANTH and the Phase 3 Common Warts Program

Author(s)Shannon Heaning, Content Associate

Test your knowledge of YCANTH and its phase 3 development program for common warts, including its current indication and COVE trials.

YCANTH (VP-102) is currently FDA approved for molluscum contagiosum and is being evaluated as a potential treatment for common warts. Test your knowledge of its current indication, the COVE phase 3 program, and what the latest enrollment milestone means for clinicians.

What is the current FDA-approved indication for YCANTH (VP-102)?

What active compound does YCANTH deliver as part of its drug-device combination?

What does the completion of enrollment in COVE-2 represent for clinicians evaluating YCANTH’s potential use in common warts?

In the COVE-2 and COVE-3 trials, how often is VP-102/TO-208 applied to patients with common warts?

Which statement best reflects the current treatment landscape for common warts?

Want to Learn More About YCANTH?

Read the full article for more on the COVE-2 enrollment milestone, phase 3 trial design, and what’s next for YCANTH in common warts.

Read the Full Article →